Tagged with Investment

Switzerland Innosuisse CEO Annalise Eggimann presents the organisation’s renewed mandate as the main Swiss innovation promotion agency, how Innosuisse serves Switzerland’s vast array of SMEs, and why the country needs to guard against complacency to stay ahead of the competition on innovation.   A successful culture needs to guard against complacency.…

USA David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term sustainability.   The life sciences industry within the United States makes significant contributions to both America’s health and economy and is a leader in R&D and innovation based on numerous proxies including patents received,…

China RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history by becoming the largest biotech IPO to date globally in 2020. It is also one of the biggest IPOs of…

Switzerland Thomas Bohn outlines how the life sciences industry in Western Switzerland has continued to perform well despite the COVID-19 pandemic, highlights some of the key recent investments in the Greater Geneva Bern area (GGBa), and gives an overview of what the region has to offer global companies across the life…

Turkey When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey’s pharma industry; the first time a Turkish firm had ever taken part in the management of a European company.   With this partnership agreement, the long trend…

Mexico COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in Mexico where the state of Hidalgo has signed a deal with six Indian generics firms to establish a pharma hub for manufacturing and logistics.   One of the leading pharma markets in Latin…

Roundup The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing struggle with COVID-19; issues around unchecked use of an anti-parasite drug; and the seismic economic and social impact of upcoming cannabis legalisation in Mexico.   Six Indian drug…

Norway Erik W. Jakobsen of Norwegian consultancy Menon Economics gives an overview of the key dynamics at play in Norway’s economy today and the growing role that healthcare and the life sciences plays within it. Jakobsen touches on why Norway needs to become more competitive as a life sciences investment destination,…

China The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as well as Bioduro and Sundio’s merger to create one of the largest CRDMOs with operations in China and the US.…

UK The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as its third largest export destination. However, with the Japanese government having previously expressed concern about uncertainties arising from the Brexit…

Norway Karita Bekkemellem of Norwegian pharma association LMI highlights her work building up the profile of the industry in Norway, the market access and pricing challenges facing her member companies, and the country’s enduring potential as a leading clinical trial destination.   Through diligent and long-term thinking, and building bridges and…

Switzerland scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0   What our members want is a good and stable…